Cardiovascular disease after renal transplantation

Kidney International, Supplement

Volumn 61, Issue 80, 2002, Pages

  Dimény, Emöke M ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Hyperhomocysteinemia; Hyperlipidemia; Metabolic risk factors; Renal transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; CREATININE; CYANOCOBALAMIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN A; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; PYRIDOXINE; RAPAMYCIN; STATIN; TACROLIMUS; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN;

ANGINA PECTORIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; GRAFT SURVIVAL; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT OUTCOME; UREMIA; BLOOD; DIABETES MELLITUS; KIDNEY DISEASE; METABOLIC DISORDER; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEINS; METABOLIC DISEASES; RISK FACTORS; UREMIA;

EID: 0035999927     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.61.s80.14.x     Document Type: Conference Paper

References (67)

1. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant
2. Patient survival after renal transplantation; more than 25 years follow-up
3. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia
4. Epidemiology of cardiovascular disease in chronic renal disease
5. Long-term survival in renal transplant recipients with graft function
6. Renal replacement therapy in Europe: The results of a collaborative effort by the ERA-EDTA registry and six national or regional registries
7. Cardiovascular morbidity and risk factors in renal transplant patients
8. Cardiovascular disease and chronic renal disease: A new paradigm
9. Explained and unexplained ischemic heart disease risk after renal transplantation
10. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease
11. Hyperlipidemia in patients with chronic renal disease
12. Post-transplant hyperlipidemia: Mechanisms and management
13. Hyperlipidemia in renal transplantation-risk factor for long-term graft outcome
14. Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?
15. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients
16. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles
17. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)
18. Lipoprotein(a) in renal disease
19. Lipoprotein(a) plasma concentrations after renal transplantation: A prospective evaluation after 4 years of follow-up
20. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?
21. Risk factors for accelerated atherosclerosis in renal transplant recipients
22. Cardiovascular disease after renal transplantation
23. Cardiovascular risk factors and diseases after renal transplantation
24. Cholesterol as an independent predictor of outcome after renal transplantation
25. Cardiac disease in diabetic end-stage renal disease
26. Atherosclerotic vascular complications in diabetic transplant candidates
27. Combined pancreas and kidney transplantation improves survival in patients with end-stage diabetic nephropathy
28. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease
29. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation
30. Management strategies for posttrans-plant hypertension
31. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension
32. Metabolic abnormalities in renal transplant recipients: Risk factors and predictors of chronic graft dysfunction?
33. Incidence and long-term cost of steroid-related side effects after renal transplantation
34. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy
35. Role of insulin resistance in human disease
36. Factors influencing weight gain after renal transplantation
37. Should obese patients lose weight before receiving a kidney transplant?
38. The effect of body mass index on long-term renal allograft survival
39. Impact and management of post-transplant diabetes mellitus
40. Metabolic cardiovascular syndrome after renal transplantation
41. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years
42. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes?
43. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation
44. Reduced fibrinolytic potential one year after kidney transplantation: Relationship to long-term steroid treatment
45. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients
46. Beneficial effects of conversion from cyclosporine fibrinolysis in renal transplant recipients
47. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients
48. Patient survival after renal transplantation: II. The impact of smoking
49. Cigarette smoking in renal transplant recipients
50. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
51. Serum total homocysteine concentration before and after renal transplantation
52. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
53. Chronic renal transplantation: A model for the hyperhomocysteinemia of renal insufficiency
54. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: Effect of treatment with folic acid
55. High cysteine levels in renal transplant recipients: Relationship with hyperhomocysteinemia and 5,10-MTHFR polymorphism
56. Homocysteine: "Expensive creatinine" or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients?
57. Serum total homocysteine concentration does not predict outcome in renal transplant recipients
58. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients
59. Early proteinuria in renal transplant recipients treated with cyclosporin
60. Proteinuria after renal transplantation affects not only graft survival but also patient survival
61. Pretransplant management of end-stage renal disease patients to minimize posttransplant risk
62. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant
63. Long-term changes in left ventricular hypertrophy after renal transplantation
64. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism
65. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study
66. Early echo-cardiographic changes and survival following renal transplantation
67. Effect of waiting time on renal transplant outcome